BioSenic S.A. (EBR:BIOS)

Belgium flag Belgium · Delayed Price · Currency is EUR
0.0023
+0.0001 (4.35%)
Oct 31, 2025, 12:51 PM CET
4.35%
Market Cap1.50M
Revenue (ttm)102.00K
Net Income (ttm)-4.77M
Shares Out652.86M
EPS (ttm)-0.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,330,732
Average Volume1,889,686
Open0.0023
Previous Close0.0023
Day's Range0.0023 - 0.0025
52-Week Range0.0012 - 0.0155
Beta-2.43
RSI42.38
Earnings DateOct 27, 2025

About BioSenic

BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company’s technologies include arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops ArsciCor, an oral medication in Phase III clinical trial and for the treatment for chronic graft-versus-host disease; JTA-004, an intra-articular injectable ... [Read more]

Industry Biotechnology
Sector Healthcare
CEO François Rieger
Employees 7
Stock Exchange Euronext Brussels
Ticker Symbol BIOS
Full Company Profile

Financial Performance

In 2024, BioSenic's revenue was 102,000, a decrease of -69.64% compared to the previous year's 336,000. Losses were -4.77 million, -83.43% less than in 2023.

Financial Statements

News

There is no news available yet.